Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Vaginitis Therapeutics
... at a CAGR of 7.5% over the analysis period 2023-2030. Anti-Bacterial, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.7 Billion by the end of the ... Read More
-
Gastroesophageal Reflux Disease (GERD) Therapeutics
... is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2023-2030. Antacids, one of the segments analyzed in the report, is expected to record a 4.4% CAGR ... Read More
-
Chronic Myelogenous Leukemia Treatment
... reach US$10.1 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and ... Read More
-
Pre-Eclampsia - Pipeline Insight, 2024
... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Pre-Eclampsia: Understanding ... Read More
-
Schizophrenia - Pipeline Insight, 2024
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Schizophrenia: Understanding Schizophrenia: ... Read More
-
Global Musculoskeletal System Disorder Market Research Report 2024
... of 4.19% during the forecast period 2024-2030. North American market for Musculoskeletal System Disorder is estimated to increase from $ 77023 million in 2023 to reach $ 100034 million by 2030, at a CAGR of ... Read More
-
Glaucoma Therapeutics
... at a CAGR of 3.5% over the analysis period 2023-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$2.9 Billion by the end of ... Read More
-
Label-free Array Systems
... by 2030, growing at a CAGR of 5.5% over the analysis period 2023-2030. Surface Plasmon Resonance (SPR) Technology, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach ... Read More
-
Hereditary Angioedema
... at a CAGR of 7.7% over the analysis period 2023-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.5 Billion by the end ... Read More
-
Biopreservation Market Report Global Forecast By Product (Equipment, Media, Laboratory Information Management System (LIMS)), Application (Regenerative Medicine, Biobanking, Drug Discovery), Countries and Company Analysis (2025-2033)
... US$ 5.44 billion in 2024 and to reach US$ 24.51 billion by 2033, with a CAGR of 18.20% during 2025-2033. The main driving factors behind this growth include the rising demand for personalized medicine, R&D ... Read More
-
Neuroprotection Therapeutics
... at a CAGR of 6.9% over the analysis period 2023-2030. Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$45.7 Billion by ... Read More
-
Sarcoma Drugs
... at a CAGR of 7.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Type 2 Diabetes - Pipeline Insight, 2024
... pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. ... Read More
-
Cutaneous T-cell lymphoma - Pipeline Insight, 2024
... drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography ... Read More
-
Lou Gehrig’s disease - Pipeline Insight, 2024
... pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. ... Read More
-
Myotonic Dystrophy - Pipeline Insight, 2024
... including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global ... Read More
-
Glioblastoma Multiforme Treatment (GBM)
... reach US$4.8 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach ... Read More
-
Guillain-Barre Syndrome Therapeutics
... by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Intravenous Immunoglobulin Therapeutics, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$541.2 Million ... Read More
-
Alpha-1 Antitrypsin Deficiency Market Insight, Epidemiology and Market Forecast – 2034
... the United States accounted for 48% of the cases, while EU4 and the UK accounted for nearly 38% and Japan represented 14% of the cases, respectively. The idiopathic inflammatory myositis market is poised for rapid ... Read More
-
Neglected Tropical Diseases Diagnosis
... reach US$10.3 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Conventional Method, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach ... Read More
-
Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
... released a research report titled “Global Epilepsy Therapeutics Market (2024 Edition)” which provides an analysis of the Global Epilepsy Therapeutics industry in terms of market segmentation By Generation (First Generation, Second Generation, Third Generation), By ... Read More
-
Myeloproliferative Disorders Drugs
... by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Ph+ Chronic myelogenous leukemia (CML) Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... reach US$4.1 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach ... Read More
-
Focal Segmental Glomerulosclerosis
... by 2030, growing at a CAGR of 6.6% over the analysis period 2023-2030. Primary Disease Type, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$17.9 Billion ... Read More
-
Desmopressin
... of 5.5% over the analysis period 2023-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$866.1 Million by the end of the analysis period. ... Read More
Research Assistance
